Eli Lilly
Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate
Eli Lilly; eloralintide; amylin candidate; weight loss; early-stage trial; obesity drug; clinical data; side effects
Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs
Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal
Eli Lilly Expands RNA Pipeline with $1.3 Billion Rznomics Hearing Loss Pact
Eli Lilly; Rznomics; RNA editing; hearing loss; gene therapy; pharmaceutical partnerships; biotech; trans-splicing ribozyme; sensorineural hearing loss; RNA therapeutics
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI
Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color
Compounders just lost their case to put obesity drug tirzepatide back in shortage
Tirzepatide, compounding, FDA, drug shortage, Eli Lilly, Zepbound, Mounjaro, legal case, Outsourcing Facilities Association (OFA), GLP-1 medications
Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact
Amyotrophic Lateral Sclerosis, Alchemab, Eli, Eli Lilly
Lilly’s Q1 revenue surge overshadowed by CVS dumping Zepbound for Wegovy
Chorionic Villi Sampling, Zepbound, Eli Lilly, Wegovy, Health
Lilly taps Creyon’s AI-enabled oligo tech in heavily backloaded $1B deal
Creyon, Eli Lilly, Eli, Oligonucleotides
Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly
Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High
Lilly continues full-court press against breast cancer with women’s March Madness event sponsorships
Eli Lilly, Woman, Madness, Malignant neoplasm of breast, Event, Awareness, Basketball game